|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||384.429 g/mol g·mol−1|
|3D model (JSmol)|
Istradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson's disease. Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.
- Peter A. LeWitt, MD, M. Guttman, James W. Tetrud, MD, Paul J. Tuite, MD, Akihisa Mori, PhD, Philip Chaikin, PharmD, MD, Neil M. Sussman, MD (2008). "Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)". Annals of Neurology. 63 (3): 295–302. doi:10.1002/ana.21315. PMID 18306243.CS1 maint: Multiple names: authors list (link)
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|